International journal of pediatric otorhinolaryngology · 2026
Balloon dilation of the eustachian tube in pediatric patients: A systematic review and meta-analysis of functional, audiological, and safety outcomes.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saade Rami, Chkaiban Farah Pamela, Elias Lara, Keyrouz Elias, Maalouf Joy, Matar Maroun
Аннотация
OBJECTIVES: To systematically review and meta-analyze the efficacy and safety of balloon dilation of the Eustachian tube (BDET) in pediatric patients with Eustachian tube dysfunction (ETD).
METHODS: PubMed, Scopus, and Web of Science were searched from inception to October 25, 2025. Original studies of any design evaluating BDET in pediatric patients were included. Outcomes included air-bone gap (ABG), pure-tone average (PTA), Eustachian tube scores, tubomanometry, Valsalva maneuver, tympanometry, tympanic membrane findings, efficacy, and complications. Mean differences (MD) and odds ratios (OR) with 95% confidence intervals (CI) were pooled using fixed- or random-effects models.
RESULTS: Twenty studies (18 retrospective, 2 prospective) involving 1175 children (1868 ears; mean age 9.1 years) were included. Within-cohort analyses showed significant ABG improvement at 6 months (MD -14.84 dB; 95% CI: -26.11 to -3.57) and 12 months (MD -10.60 dB; 95% CI: -18.29 to -2.90). Eustachian tube scores significantly improved (MD 3.78; 95% CI: 2.85-4.71), and negative Valsalva results were significantly reduced after BDET (OR 17.21; 95% CI: 6.87-43.12). However, comparative analyses versus controls showed no significant differences in ABG or efficacy/cure rates (OR 1.08; 95% CI: 0.31-3.73). PTA and tubomanometric resistance scores showed no significant changes. The pooled efficacy rate was 67%, and the pooled complication rate was 3% (95% CI, 2-4%). Heterogeneity was high, and most studies were of fair quality.
CONCLUSION: BDET may improve functional and audiological outcomes in pediatric ETD, but current comparative evidence does not confirm superiority over standard management. Higher-quality prospective randomized studies are needed.
METHODS: PubMed, Scopus, and Web of Science were searched from inception to October 25, 2025. Original studies of any design evaluating BDET in pediatric patients were included. Outcomes included air-bone gap (ABG), pure-tone average (PTA), Eustachian tube scores, tubomanometry, Valsalva maneuver, tympanometry, tympanic membrane findings, efficacy, and complications. Mean differences (MD) and odds ratios (OR) with 95% confidence intervals (CI) were pooled using fixed- or random-effects models.
RESULTS: Twenty studies (18 retrospective, 2 prospective) involving 1175 children (1868 ears; mean age 9.1 years) were included. Within-cohort analyses showed significant ABG improvement at 6 months (MD -14.84 dB; 95% CI: -26.11 to -3.57) and 12 months (MD -10.60 dB; 95% CI: -18.29 to -2.90). Eustachian tube scores significantly improved (MD 3.78; 95% CI: 2.85-4.71), and negative Valsalva results were significantly reduced after BDET (OR 17.21; 95% CI: 6.87-43.12). However, comparative analyses versus controls showed no significant differences in ABG or efficacy/cure rates (OR 1.08; 95% CI: 0.31-3.73). PTA and tubomanometric resistance scores showed no significant changes. The pooled efficacy rate was 67%, and the pooled complication rate was 3% (95% CI, 2-4%). Heterogeneity was high, and most studies were of fair quality.
CONCLUSION: BDET may improve functional and audiological outcomes in pediatric ETD, but current comparative evidence does not confirm superiority over standard management. Higher-quality prospective randomized studies are needed.